A Pilot Study of the PI3K Inhibitor BKM120 in Patients With Relapsed Lymphoma

Trial Profile

A Pilot Study of the PI3K Inhibitor BKM120 in Patients With Relapsed Lymphoma

Completed
Phase of Trial: Phase II

Latest Information Update: 29 Mar 2017

At a glance

  • Drugs Buparlisib (Primary)
  • Indications B cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 24 Mar 2017 Status changed from active, no longer recruiting to completed.
    • 20 Dec 2016 Planned primary completion date changed from 1 Sep 2016 to 1 Sep 2017.
    • 24 Jun 2015 Planned primary completion date changed from 1 Sep 2014 to 1 Sep 2016 as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top